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Medicines optimisation is a key role for hospital clinical
pharmacists1, but with increasing demands on services
there is a need to increase efficiency whilst maintaining
patient safety. Clinical prioritisation has been proposed
as a way to permit pharmacy services to focus on where
the need is greatest2. The aim of this study was to develop
and test a prediction tool, the Medicines Optimisation
Assessment Tool (MOATTM), to target patients at highest
risk of medication related problems (MRPs) while in hos-
pital. The objectives were to develop a decision aid to
allocate patients to risk groups, and to assess its predic-
tive performance and clinical usefulness.
Consecutive admissions (n = 1652) from adult medical
wards at two UK hospitals were prospectively included
into this cohort study between April and November 2016.
Elective admissions were excluded, as were patients not
prescribed medication, and/or whose prescribing records
were not reviewed by a pharmacist. Data on MRPs were
collected by pharmacists as part of their routine daily clin-
ical assessments. Data on potential risk factors, such as
number of comorbidities and use of “high-risk” medici-
nes, were collected retrospectively. A prognostic model
was developed using multivariable logistic regression to
determine the relationship between potential risk factors
and the study outcome: patients with at least one moder-
ate or severe preventable MRP, and a simplified elec-
tronic scoring system (the MOAT) was developed. Three
risk groups were created to guide prioritisation. Predictive
performance was assessed using discrimination (concor-
dance index) and calibration. Sensitivity and specificity
were calculated, and clinical usefulness assessed using
decision curve analysis. Ethical approval was obtained
from the proportionate review service sub-committee of
the National Health Service Research Ethics Committee,
Wales REC 7 (16/WA/0016).
Among 1503 eligible patient admissions, 610 (40.6%)
experienced the study outcome. Eleven variables were
retained in the final model: number of comorbidities,
number of medicines, white cell count, renal function,
previous allergy, aminoglycosides/glycopeptides, other
antimicrobials, epilepsy medicines, and 3 primary diag-
noses (nervous system/mental disorders, respiratory and
gastrointestinal). The MOAT demonstrated fair predic-
tive performance: (concordance index 0.66) and good
calibration. The decision thresholds between risk groups
had sensitivities of 90% and 66% (specificity 30% and
61% respectively). The MOAT has potential to increase
the efficiency of hospital pharmacy services by identify-
ing the 22% of patients least likely to experience a mod-
erate or severe preventable MRP. Decision curve
analysis suggests the MOAT has the potential to be clin-
ically useful at the thresholds selected to categorise
patients as low, medium and high-risk.
The MOAT is the first evidence-based clinical priori-
tisation tool to identify patients most in need of phar-
macists’ input in terms of their risk of moderate or
severe preventable MRPs, experienced by 41% of admis-
sions. Results suggest acceptable predictive accuracy,
with decision curve analysis demonstrating potential
clinical usefulness. A strength of this research is adher-
ence with recommendations of the PROGnosis
RESearch Strategy (PROGRESS) partnership. Limita-
tions include the observational nature of the study,
meaning residual confounding cannot be excluded.
The next step is to assess the MOAT’s clinical credi-
bility. Extensive external validation, involving prospec-
tive validation in a new cohort, will also be required,
together with studies to assess the impact of the MOAT
in clinical practice.
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The General Practice Forward View (GPFV) outlined
the NHS England strategy for general practice in Eng-
land.1 The GPFV outlined an investment of £31 million
to pilot 470 clinical pharmacists in over 700 practices.
This work was commissioned to evaluate the Phase 1
pilot.2 Amongst a number of outcomes the evaluation
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was tasked to investigate the impact the initiative had
on the pharmacists’ general practices and patients.
A mix of quantitative and qualitative approaches
were used. An online questionnaire was developed and
piloted prior to distribution to pharmacists employed as
part of the NHS England pilot. The survey explored a
wide range of areas from recruitment and skills, to work
practices and outcomes of the programme. Two remin-
ders were sent to non-responders. Analysis consisted of
descriptive statistics and thematic review of free-text
responses. Sites were also explored in depth using an
ethnographic case study approach. Case studies included
interviews with pharmacists, site leads and general prac-
titioners along with patient focus groups. Topic guides
for these were open-ended, focussing on capturing
descriptions and experiences of the pharmacists’ role.
This work was service evaluation and did not therefore
need ethical review.
Survey responses were received from 159 pharmacists
out of the 379 pharmacists with known email addresses
(42% response rate). 89% (142/159) reported enjoying
working in their role with the same number reporting
that they could work autonomously and are accepted by
other members of the practice team. Pharmacists
reported impacting significantly on medicines optimisa-
tion, especially safety, through becoming responsible for
the management of repeat medicines, including a num-
ber of reports of notable deprescribing. In-depth case
studies were conducted in three sites with additional
interviews conducted in a further five. All sites reported
that once established, the pharmacists increased capacity
in the practice with more GP appointments available to
patients, in addition to new pharmacist appointments.
Patients reported significant improvements in their
understanding of their medicines.
“I sat with her and gave all the dietary advice and
made her fill in a food diary and exercise diary and
it was quite unique because she’d never done those
sort of things before. I spoke to her about her medi-
cation because she was very non-compliant” Phar-
macist Site C
“. . . I have only seen [pharmacist] the once but she
spent a lot of time with me, I was in there for 20
minutes. I was impressed with that. I have never
had that level of service in this surgery.” Patient
Site C
The data gathered suggests that the clinical pharma-
cists in the phase 1 pilot had significant impact on the
pharmacists, the general practice and patients. With
pharmacists feeling valued as professionals, practices
with increased capacity for GP appointments through
task transfer and patients satisfied through increased
understanding of their medicines. This evaluation looked
only at the NHS England Phase 1 pharmacists and was
constrained in the time available, meaning a comprehen-
sive review was not possible and it may therefore not
reflect wider practice. Further evaluation is necessary to
quantify benefit.
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